| Symbol | ELUT |
|---|---|
| Name | ELUTIA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 12510 PROSPERITY DRIVE, SILVER SPRING, MD 20904 |
| Telephone | 240-247-1143 |
| Fax | — |
| — | |
| Website | https://www.aziyo.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001708527 |
| Description | Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. Additional info from NASDAQ: |
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNew Form SCHEDULE 13G/A - ELUTIA INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-096804 <b>Size:</b> 8 KB
Read moreElutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Read moreNew Form SCHEDULE 13G - ELUTIA INC. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001104659-26-093849 <b>Size:</b> 8 KB
Read moreElutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06854081 | EluPro Antibiotic-Eluting BioEnvelope Registry | — | Cardiac Arrhythmias | Active_Not_Recruiting | 2025-04-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT04299282 | CIED Implantation in Low BMI Patients | Na | Heart Diseases | Withdrawn | 2021-06-01 | 2022-03-01 | ClinicalTrials.gov |
| NCT04846127 | CanGaroo® Registry Study | — | Arrhythmias, Cardiac | Completed | 2021-05-25 | 2024-10-17 | ClinicalTrials.gov |
| NCT04645173 | Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, o… | — | Cardiac Disease | Completed | 2021-02-02 | 2023-12-31 | ClinicalTrials.gov |
| NCT04351269 | Retrospective Experience Of CIED Implantation | — | Cardiac Disease | Completed | 2020-04-22 | 2021-06-30 | ClinicalTrials.gov |
| NCT04060134 | A Retrospective Breast Reconstruction Study | — | Breast Cancer | Completed | 2019-11-20 | 2022-06-01 | ClinicalTrials.gov |
| NCT03896347 | A Study Evaluating 3-Level OLIF Spine Fusion | — | Spondylolisthesis | Withdrawn | 2019-07-01 | 2020-02-13 | ClinicalTrials.gov |
| NCT03425682 | ViBone in Cervical and Lumbar Spine Fusion | — | Spondylosis | Completed | 2018-05-14 | 2021-06-30 | ClinicalTrials.gov |
| NCT02530970 | A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matri… | — | Cardiovascular Disease | Completed | 2015-10-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02418143 | A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM®… | — | Coronary Disease | Withdrawn | 2015-09-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02418156 | A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction | — | Peripheral Vascular Disease | Completed | 2015-05-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02073331 | Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix) | — | Coronary Disease | Completed | 2014-03-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01569594 | CorMatrix ECM for Carotid Repair Following Endarterectomy Registry | — | Carotid Stenosis | Completed | 2012-04-01 | 2016-12-31 | ClinicalTrials.gov |
| NCT01247974 | Evaluation Of New Onset Postoperative Atrial Fibrillation | Na | Atrial Fibrillation New Onset | Completed | 2010-12-01 | 2012-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EluPro Antibiotic-Eluting BioEnvelope | Other | Preclinical | Cardiac Arrhythmias | ACTIVE_NOT_RECRUITING | NCT06854081 |
| Bone Morphogenetic Protein | Other | Preclinical | Spondylolisthesis | WITHDRAWN | NCT03896347 |
| Demineralized Bone Matrix | Other | Preclinical | Spondylolisthesis | WITHDRAWN | NCT03896347 |
| ViBone® | Other | Preclinical | Spondylolisthesis | WITHDRAWN | NCT03896347 |
| CorMatrix CanGaroo ECM Envelope | Other | Preclinical | Coronary Disease | WITHDRAWN | NCT02418143 |
| TYRX Envelope | Other | Preclinical | Cardiac Disease | COMPLETED | NCT04351269 |
| CanGaroo Envelope | Other | Preclinical | Cardiac Disease | COMPLETED | NCT04351269 |
| CorMatrix ECM for Vascular Repair | Other | Preclinical | Peripheral Vascular Disease | COMPLETED | NCT02418156 |
| CorMatrix ECM for Carotid Repair | Other | Preclinical | Carotid Stenosis | COMPLETED | NCT01569594 |
| CorMatrix ECM for Pericardial Closure | Other | Approved | Atrial Fibrillation New Onset | COMPLETED | NCT01247974 |
| CIED envelope | Other | Preclinical | Cardiac Disease | COMPLETED | NCT04645173 |
| DermACELL HADM | Other | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| FlexHD HADM | Other | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| AlloMax HADM | Other | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| AlloDerm HADM | Other | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| SimpliDerm HADM | Other | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| ViBone | Other | Preclinical | Spondylosis | COMPLETED | NCT03425682 |
| CanGaroo Envelope | Other | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT04846127 |
| CanGaroo | Other | Approved | Heart Diseases | WITHDRAWN | NCT04299282 |
| EluPro Antibiotic-Eluting BioEnvelope | Other | Preclinical | Cardiac Arrhythmias | RECRUITING | NCT06854081 |
| CIED envelope | DEVICE | Preclinical | Cardiac Disease | COMPLETED | NCT04645173 |
| TYRX Envelope | DEVICE | Preclinical | Cardiac Disease | COMPLETED | NCT04351269 |
| CanGaroo Envelope | DEVICE | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT04846127 |
| CanGaroo | DEVICE | Approved | Heart Diseases | WITHDRAWN | NCT04299282 |
| DermACELL HADM | OTHER | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| FlexHD HADM | OTHER | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| AlloMax HADM | OTHER | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| AlloDerm HADM | OTHER | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| SimpliDerm HADM | OTHER | Preclinical | Breast Cancer | COMPLETED | NCT04060134 |
| Bone Morphogenetic Protein | OTHER | Preclinical | Spondylolisthesis | WITHDRAWN | NCT03896347 |
| Demineralized Bone Matrix | OTHER | Preclinical | Spondylolisthesis | WITHDRAWN | NCT03896347 |
| ViBone® | OTHER | Preclinical | Spondylolisthesis | WITHDRAWN | NCT03896347 |
| ViBone | OTHER | Preclinical | Spondylosis | COMPLETED | NCT03425682 |
| CorMatrix ECM for Vascular Repair | DEVICE | Preclinical | Peripheral Vascular Disease | COMPLETED | NCT02418156 |
| CorMatrix CanGaroo ECM Envelope | DEVICE | Preclinical | Coronary Disease | WITHDRAWN | NCT02418143 |
| CorMatrix ECM for Carotid Repair | DEVICE | Preclinical | Carotid Stenosis | COMPLETED | NCT01569594 |
| CorMatrix ECM for Pericardial Closure | DEVICE | Approved | Atrial Fibrillation New Onset | COMPLETED | NCT01247974 |